CHATSWORTH, Calif. - Chad Therapeutics, the pioneering oxygen conserver company, has set its sights on the sleep market.
Chad has signed product development and license agreements with AirMatrix Technologies and Acoba of St. Louis, Mo., privately held engineering and technology companies focused on the development of therapeutic gas monitoring and delivery systems.
Chad isn't saying much about the sleep technology that's stimulated its interest in the sleep disordered breathing market. In joint development by an internal team at Chad and Acaboa, it will be 12-24 months before the initial products are ready to market. Chad expects to fund the development program from the company's operational cash flow. HME
Comments